Align will continue to lead in the removal aligner field.
Created when NASDAQ:ALGN was $18.24 | Edit | History
As of yet no contender on the horizon. Several companies have launched express versions of aligners but none with the exception of Clear Correct have anything approaching full arch orthodontic alignment. The FDA has become extremely rigorous in their 510K granting process to point of blocking new players, e.g. Densply/GAC. Their IP on the transfer of digital sequencial corrected models to the SLA process is secure and is leading edge tech. While regular orthodontist in the main dislike the organization they are locked in with the referral system and marketing support.